BioWorld

Norwegian University of Science and Technology divulges new CSF-1R inhibitors

Norwegian University of Science and Technology (NTNU) has synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of ...
ascopubs.org

First-in-human study of simmitinib, a novel tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R.

First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.
FiercePharma

Incyte, Syndax bag FDA approval for potential blockbuster Niktimvo in graft-versus-host disease

Incyte has expanded its graft-versus-host disease (GVHD) offerings beyond Jakafi. The new addition comes from axatilimab, a CSF-1R inhibitor partnered with Syndax Pharmaceuticals. Wednesday, the drug ...
BioWorld

China approves Abbisko/Merck’s CSF-1R inhibitor pimicotinib

Abbisko Therapeutics Co. Ltd. and its partner Merck KGaA got an early Christmas present from China’s National Medical Products Administration (NMPA) with the approval of pimicotinib (ABSK-021), the ...
Nasdaq

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson’s disease and obesity in H2 ...